Interestingly, clinical data from MS patients suggest that regulatory B cells with increased expression of CD5 predominantly repopulate following anti-CD20 treatment, which—when activated—secrete more anti-inflammatory IL-10 (209). This evidence concerns the gene IL10 and myeloid sarcoma.